Aveta Biomics Announces Podium Presentation of Registrational Phase 3 Head and Neck Cancer Trial at AHNS 2026 Conference
Global Phase 3 study of first oral immunotherapy designed to work independent of PD-L1 across “hot” and “cold” tumors in locally advanced head and neck cancer BEDFORD, MA, UNITED STATES, March 24, 2026 /EINPresswire.com/ -- Aveta Biomics, a …